ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the...
本文就本届会议上转移性结直肠癌(metastatic colorectal cancer,mCRC)免疫和靶向治疗领域的进展予以介绍和述评。 1 免疫治疗近年来,免疫治疗取得突飞猛进的发展。对于mCRC的免疫治疗进展,主要分为错配修复蛋白正常(proficient mismatch repair,pMMR...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice...
[2-4]. Previously, HANSIZHUANG was approved in China for the treatment of MSI-H solid tumours in March 2022 based on its excellent efficacy data, and then was recommended by the CSCO Guidelines for Colorectal Cancer and the CSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor. The ...
[2-4]. Previously, HANSIZHUANG was approved in China for the treatment of MSI-H solid tumours in March 2022 based on its excellent efficacy data, and then was recommended by the CSCO Guidelines for Colorectal Cancer and the CSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor. The ...
[2-4]. Previously, HANSIZHUANG was approved in China for the treatment of MSI-H solid tumours in March 2022 based on its excellent efficacy data, and then was recommended by theCSCO Guidelines for Colorectal Cancerand theCSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor. The ...
ASCO Endorsement of ESMO Guidelines on Hereditary Colorectal Cancer SyndromesPatrick M. Lynch
Overall, any history of bisphosphonate use was associated with a 33% lower risk of colorectal cancer. Analysis of the data by duration of bisphosphonate therapy showed that the beneficial effect on colorectal cancer risk began after 1 year of treatment. Women who used bisphosphonates for less...
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update Wird in neuem Tab/Fenster geöffnet Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis Wird ...